Aurora Cannabis Inc
TSX:ACB
Aurora Cannabis Inc
Aurora Cannabis, Inc. engages in the production, distribution and sale of cannabis products. The firm's principal business lines are focused on the production, distribution and sale of cannabis and cannabis related products in Canada and internationally. The firm's portfolio of brands includes Aurora, Aurora Drift, San Rafael '71, Daily Special, MedReleaf, CanniMed, Whistler, Reliva and KG7 CBD. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia; and Odense, Denmark. The firm is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets. The company produces approximately 150,000 kilograms (kg) of cannabis biomass annually. Its subsidiaries include 1769474 Alberta Ltd., 2105657 Alberta Inc., Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Aurora Nordic Cannabis A/S, and Reliva, LLC, among others.
Aurora Cannabis, Inc. engages in the production, distribution and sale of cannabis products. The firm's principal business lines are focused on the production, distribution and sale of cannabis and cannabis related products in Canada and internationally. The firm's portfolio of brands includes Aurora, Aurora Drift, San Rafael '71, Daily Special, MedReleaf, CanniMed, Whistler, Reliva and KG7 CBD. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia; and Odense, Denmark. The firm is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets. The company produces approximately 150,000 kilograms (kg) of cannabis biomass annually. Its subsidiaries include 1769474 Alberta Ltd., 2105657 Alberta Inc., Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Aurora Nordic Cannabis A/S, and Reliva, LLC, among others.
Revenue Growth: Aurora reported Q3 net revenue of $94.2 million, up 7% year-over-year, driven by strong medical cannabis sales.
Medical Cannabis Strength: Global medical cannabis revenue hit $76.2 million, up 12%, with international markets growing 17%. Medical cannabis made up 81% of net revenue.
Margin Expansion: Adjusted gross margin improved by 100 basis points to 62%, with medical cannabis margins holding firm at 69%.
Profitability & Cash Flow: The company posted adjusted EBITDA of $18.5 million, adjusted net income of $7.2 million, and free cash flow of $15.5 million. Cash balance was $154 million, with no cannabis business debt.
Strategic Refocus: Aurora is exiting select lower-margin Canadian consumer cannabis markets and divesting its plant propagation business to focus on higher-margin global medical cannabis.
Full-Year Guidance: Management expects annual global medical cannabis revenue of $269–$281 million and adjusted EBITDA of $52–$57 million, citing 10–15% growth in medical cannabis.
International Performance: Germany drove international growth; Australia is transitioning to premium products; Poland maintained leadership despite regulatory shifts.
ATM Equity Program: A new at-the-market equity facility allows up to $100 million in share issuance for strategic purposes, including cultivation expansion and M&A.
